Evolution of insulin development: Focus on key parameters

Advances in Therapy

Volumn 29, Issue 7, 2012, Pages 590-619

  Tibaldi, Joseph M ^a  

^a NONE   (United States)

Author keywords

Animal insulin; Diabetes; Hypoglycemia; Insulin; Insulin analogs; Regular human insulin; Synthetic insulin

Indexed keywords

BOVINE INSULIN; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LY 2605541; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIG INSULIN; PIOGLITAZONE; RECOMBINANT HUMAN INSULIN; SULFONYLUREA; SYNTHETIC INSULIN; UNCLASSIFIED DRUG; VALSARTAN;

ABSCESS; ADD ON THERAPY; ANTIBODY PRODUCTION; BOLUS INJECTION; CANCER RISK; CARDIOVASCULAR DISEASE; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIFESTYLE; LIPOATROPHY; LIPODYSTROPHY; LIVER CANCER; MAXIMUM PLASMA CONCENTRATION; MITOGENICITY; MORNING DOSAGE; MORTALITY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PATIENT COMPLIANCE; RECOMBINANT DNA TECHNOLOGY; REVIEW; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84866559820     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0034-8     Document Type: Review

References (153)

1. Deckert T, Andersen OO, Poulsen JE The clinical significance of highly purified pig-insulin preparations Diabetologia 1974;10:703-8.
2. Hirsch IB Insulin analogues N Engl J Med 2005;352:174-83.
3. Pieber TR, Treichel HC, Hompesch B, et al Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy Diabet Med 2007;24:635-42.
4. Garg SK, Gottlieb PA, Hisatomi ME, et al Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine Diabetes Res Clin Pract 2004;66:49-56.
5. Devries JH, Nattrass M, Pieber TR Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007;23:441-54.
6. Mudaliar SR, Lindberg FA, Joyce M, et al Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects Diabetes Care 1999;22:1501-6.
7. Cernea S, Raz I Noninjectable methods of insulin administration Drugs Today (Barc) 2006;42:405-24.
8. Kalra S, Kalra B, Agrawal N Oral insulin Diabetol Metab Syndr 2010;2:66-9.
9. Still JG Development of oral insulin: progress and current status Diabetes Metab Res Rev 2002;18 (Suppl 1):S29-S37.
10. Howey DC, Bowsher RR, Brunelle RL, Woodworth Jr [Lys(B28), Pro(B29)]-human insulin A rapidly absorbed analogue of human insulin Diabetes 1994;43:396-402.
11. Davis SN Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas In: Brunton LL, Lazo JS, Parker KL, eds Goodman & Gilman's The Pharmacological Basis of Therapeutics 11th edition New York: McGraw-Hill; 2006:1613-45.
12. Felig P Landmark perspective: protamine insulin Hagedorn's pioneering contribution to drug delivery in the management of diabetes JAMA 1984;251:393-6.
13. Rosenfeld L Insulin: discovery and controversy Clin Chem 2002;48:2270-88.
14. Marble A Hypoglycemia due to insulin N Engl J Med 1937;217:130-6.
15. Krayenbuhl C, Rosenberg T Crystalline protamine insulin Rep Steno Mem Hosp 1946;1:60-73.
16. Vajo Z, Fawcett J, Duckworth WC Recombinant DNA technology in the treatment of diabetes: insulin analogs Endocr Rev 2001;22:706-17.
17. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo Diabetes Care 2000;23:644-9.
18. Binder C, Lauritzen T, Faber O, Pramming S Insulin pharmacokinetics Diabetes Care 1984;7:188-99.
19. Guthrie R Is there a need for better basal insulin? Clin Diabetes 2001; 19:66-70.
20. Wright AD, Walsh CH, Fitzgerald MG, Malins JM Very pure porcine insulin in clinical practice BMJ 1979;1:25-7.
21. McNally PG, Jowett NI, Kurinczuk JJ, Peck RW, Hearnshaw Jr Lipohypertrophy and lipoatrophy complicating treatment with highly purified bovine and porcine insulins Postgrad Med J 1988;64:850-3.
22. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus N Engl J Med 1976;295:417-20.
23. Lebovitz HE, Austin MM, Blonde L, et al ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations Endocr Pract 2006;12 (Suppl 1):6-12.
24. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose The Funagata Diabetes Study Diabetes Care 1999;22:920-4.
25. Holman RR, Haffner SM, McMurray JJ, et al Effect of nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med 2010;362:1463-76.
26. Raz I, Ceriello A, Wilson PW, et al Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia Diabetes Care 2011;34:1511-13.
27. Kung YT, Du YC, Huang WT, Chen CC, Ke LT Total synthesis of crystalline insulin Sci Sin 1966;15:544-61.
28. Katsoyannis PG, Tometsko A, Zalut C Insulin peptides XII Human insulin generation by combination of synthetic A and B chains J Am Chem Soc 1966;88:166-7.
29. Teuscher A The biological effect of purely synthetic human insulin in patients with diabetes mellitus Schweiz Med Wochenschr 1979;109:743-7 In German.
30. Zhang Y The first protein ever synthesized in vitro -a personal reminiscence of the total synthesis of crystalline insulin Sci China Life Sci 2010;53:16-18.
31. Owens DR, Jones MK, Hayes TM, et al Human insulin: study of safety and efficacy in man BMJ (Clin Res Ed) 1981;282:1264-6.
32. Sestoft L, Volund A, Gammeltoft S, Birch K, Hildebrandt P The biological properties of human insulin Subcutaneous absorption, receptor binding and the clinical effect in diabetics assessed by a new statistical method Acta Med Scand 1982;212:21-8.
33. Goeddel DV, Kleid DG, Bolivar F, et al Expression in Escherichia coli of chemically synthesized genes for human insulin Proc Natl Acad Sci USA 1979;76:106-10.
34. Joshi SR, Parikh RM, Das AK Insulin -history, biochemistry, physiology and pharmacology J Assoc Physicians India 2007;55 (Suppl.):19-25.
35. Powers AC Diabetes Mellitus In: Longo DL, Fauci AS, Kasper DL, et al., eds Harrison's Principles of Internal Medicine 18th edition New York: McGraw-Hill; 2012: 2968-3002.
36. Eli Lilly and Company Heritage Available at: http://www.lilly.com/about/ heritage/Pages/heritage.aspx Accessed July 17, 2012.
37. Eli Lilly and Company Humulin® R (regular insulin human injection [rDNA origin]) 100 units per mL (U-100) [prescribing information] Indianapolis, IN: Eli Lilly and Company; March 25,2011.
38. Eli Lilly and Company Humulin® N (NPH human insulin [rDNA origin]) [prescribing information] Indianapolis, IN: Eli Lilly and Company; September 2, 2009.
39. Keen H, Glynne A, Pickup JC, et al Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men Lancet 1980;2:398-401.
40. Novo Nordisk Inc Milestones in Novo Nordisk's history Available at: http://www.novonordisk com/about-us/history/milestones-in-nn-history asp Accessed July 17, 2012.
41. Brunton S Safety and effectiveness of modern insulin therapy: the value of insulin analogs Consultant 2009;July 29 (Suppl.):S13-S19.
42. Clark AJ, Adeniyi-Jones RO, Knight G, et al Biosynthetic human insulin in the treatment of diabetes A double-blind crossover trial in established diabetic patients Lancet 1982;2:354-7.
43. Hildebrandt P, Birch K, Sestoft L, Volund A Dose-dependent subcutaneous absorption of porcine, bovine and human NPH insulins Acta Med Scand 1984;215:69-73.
44. Heinemann L Do insulin-treated diabetic patients use an injection-meal-interval in daily life? Diabet Med 1995;12:449-50.
45. Eli Lilly and Company Humulin® 70/30 70% human insulin isophane suspension and 30% human insulin injection (rDNA origin) 100 units per ML (U-100) [prescribing information] Indianapolis, IN: Eli Lilly and Company; January 20, 2011.
46. Novo Nordisk Inc Novolin® 70/30 [patient information] Princeton, NJ: Novo Nordisk Inc.; May 14, 2010.
47. Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe Diabetes Technol Ther 2009;11:529-38.
48. Hartman I Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence Clin Med Res 2008;6:54-67.
49. Yamada S Insulin glulisine in the management of diabetes Diabetes Metab Syndr Obes 2009;2:111-15.
50. Owens DR Insulin preparations with prolonged effect Diabetes Technol Ther 2011;13 (Suppl 1):S5-S14.
51. Poon K, King AB Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogs Drug Healthc Patient Saf 2010;2:213-23.
52. Novo Nordisk Inc Levemir® (insulin detemir [rDNA origin] injection) [prescribing information] Princeton, NJ: Novo Nordisk Inc.; May 18, 2012.
53. Sanofi-Aventis U.S Lantus® (insulin glargine [rDNA origin] injection) [prescribing information] Bridgewater, NJ: Sanofi-Aventis; April, 2010.
54. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites Diabetes Care 2000;23:813-19.
55. Porcellati F, Rossetti P, Ricci BN, et al Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study Diabetes Care 2007;30:2447-51.
56. Plank J, Bodenlenz M, Sinner F, et al A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir Diabetes Care 2005;28:1107-12.
57. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes Diabetes Obes Metab 2007;9:290-9.
58. Bolli GB, Luzio S, Marzotti S, et al Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes Diabetes Obes Metab 2011;13:251-7.
59. Rave K, Bott S, Heinemann L, et al Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin Diabetes Care 2005;28:1077-82.
60. Tamas G, Marre M, Astorga R, Dedov I, Jacobsen J, Lindholm A Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study Diabetes Res Clin Pract 2001;54:105-14.
61. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects Diabetes Care 2003;26:2027-31.
62. Becker RH, Frick AD Clinical pharmacokinetics and pharmacodynamics of insulin glulisine Clin Pharmacokinet 2008;47:7-20.
63. Becker RHA, Frick AD, Burger F, Potgieter JH, Scholtz H Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects Exp Clin Endocrinol Diabetes 2005;113:435-43.
64. Heise T, Nosek L, Spitzer H, et al Insulin glulisine: a faster onset of action compared with insulin lispro Diabetes Obes Metab 2007;9:746-53.
65. Luzio S, Peter R, Dunseath GJ, Mustafa L, Owens DR A comparison of preprandial insulin glulisine versus insulin lispro in people with type 2 diabetes over a 12-h period Diabetes Res Clin Pract 2008;79:269-75.
66. Meyer C, Boron A, Plummer E, Voltchenok M, Vedda R Glulisine versus human regular insulin in combination with glargine in noncritically ill hospitalized patients with type 2 diabetes: a randomized double-blind study Diabetes Care 2010;33:2496-501.
67. Home PD, Barriocanal L, Lindholm A Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers Eur J Clin Pharmacol 1999;55:199-203.
68. Rolla A Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety Am J Med 2008; 121 (6 Suppl.):S9-S19.
69. Garber AJ, Ligthelm R, Christiansen JS, Liebl A Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007;9:630-9.
70. Hermansen K, Colombo M, Storgaard H, OStergaard A, Kolendorf K, Madsbad S Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes Diabetes Care 2002;25:883-8.
71. Weyer C, Heise X Heinemann L Insulin aspart in a 30/70 premixed formulation Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture Diabetes Care 1997;20:1612-14.
72. Heise X Heinemann L, Hovelmann U, et al Biphasic insulin aspart 30/70 (BIAsp 30): pharmacokinetics (PK) and pharmacodynamics (PD) in comparison with once-daily biphasic human insulin and basal-bolus therapy Diabetes Care 2009;32:1431-3.
73. Handelsman Y, Mechanick JI, Blonde L, et al American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan Endocr Pract 2011;17 (Suppl 2):1-53.
74. American Diabetes Association Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia Diabetes Care 2005;28:1245-9.
75. Taborsky GJ, Ahren B, Havel PJ Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired a-cell responses in type 1 diabetes Diabetes 1998;47:995-1005.
76. Bolli G, De Feo P, Compagnucci P, et al Abnormal glucose counterregulation in insulin-dependent diabetes mellitus Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion Diabetes 1983;32:134-41.
77. Cryer PE Banting Lecture Hypoglycemia: the limiting factor in the management of IDDM Diabetes 1994;43:1378-89.
78. Cryer PE Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention Alexandria, VA: American Diabetes Association; 2009.
79. UK Hypoglycaemia Study Group Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration Diabetologia 2007;50:1 140-7.
80. United Kingdom Prospective Diabetes Study 24 A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy United Kingdom Prospective Diabetes Study Group Ann Intern Med 1998;128:165-75.
81. Rys P, Pankiewicz O, Lach K, Kwaskowski A, Skrzekowska-Baran I, Malecki MT Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review Diabetes Metab 2011;37:190-200.
82. Brunetti P, Muggeo M, Cattin L, et al Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine Nutr Metab Cardiovasc Dis 2010;20:519-26.
83. Riddle MC, Rosenstock J, Gerich J The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 2003;26:3080-6.
84. The ORIGIN Trial Investigators Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 2012; Jun 11 [Epub ahead of print].
85. Le Floch JP Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics Diabetes Metab Syndr Obes 2010;3:197-213.
86. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetes Care 2006;29:1269-74.
87. Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes Clin Ther 2006;28:1569-81.
88. Martorella AJ Iatrogenic hypoglycemia in patients with type 2 diabetes: comparison of insulin analog premixes and human insulin premixes Postgrad Med 2011;123:7-16.
89. Davidson JA, Liebl A, Christiansen JS, et al Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis Clin Ther 2009;31:1641-51.
90. Morgan CL, Evans M, Toft AD, Jenkins-Jones S, Poole CD, Currie CJ Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study Clin Ther 2011;33:27-35.
91. Valensi P, Benroubi M, Borzi V, et al Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study Int J Clin Pract 2009;63:522-31.
92. Anderson JH Jr., Brunelle RL, Koivisto VA, et al Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment Multicenter Insulin Lispro Study Group Diabetes 1997;46:265-70.
93. Home PD, Lindholm A, Hylleberg B, Round P Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients Diabetes Care 1998;21:1904-9.
94. Garg S, Ampudia-Blasco FJ, Pfohl M Rapid-acting insulin analogues in basal-bolus regimens in type 1 diabetes mellitus Endocr Pract 2010;16:486-505.
95. American Diabetes Association Standards of medical care in diabetes -2012 Diabetes Care 2012;35 (Suppl 1):S11-S63.
96. Lepore M, Pampanelli S, Fanelli C, et al Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro Diabetes 2000;49:2142-8.
97. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes Diabetologia 2004;47:622-9.
98. Davidson MB, Navar MD, Echeverry D, Duran P U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients Diabetes Care 2010;33:281-3.
99. Garg R, Johnston V, McNally PG, Davies MJ, Lawrence IG U-500 insulin: why, when and how to use in clinical practice Diabetes Metab Res Rev 2007;23:265-8.
100. Lane WS, Cochran EK, Jackson JA, et al High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 2009;15:71-9.
101. De La Pena A, Riddle M, Morrow LA, et al Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects Diabetes Care 2011;34:2496-501.
102. Lowery JB, Donihi AC, Korytkowski MT U-500 insulin as a component of basal bolus insulin therapy in type 2 diabetes Diabetes Technol Ther 2012;14:505-7.
103. Heise T, Tack CJ, Cuddihy R, et al A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial Diabetes Care 2011;34:669-74.
104. Birkeland KI, Home PD, Wendisch U, et al Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine Diabetes Care 2011;34:661-5.
105. Simon AC, Devries JH The future of basal insulin supplementation Diabetes Technol Ther 2011;31 (Suppl 1):S108.
106. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin Pharmaceutical Research 2012; Apr 7 [Epub ahead of print].
107. Arnolds S, Kuglin B, Kapitza C, Heise T How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes Int J Clin Pract 2010;64:1415-34 Available at: http://professional diabetes org/Abstracts-Display aspx?TYP=1&CID=86498 Accessed July 10, 2012.
108. Heise X Hovelmann U, Nosek L, Bottcher SG, Granhall C, Haahr H Insulin degludec: two-fold longer half-life and more consistent pharmacokinetic profile than insulin glargine Diabetologia 2011;54:s425.
109. Heller S, Francisco AM, Pei H, Russell-Jones D Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in type 1 diabetes [abstract] Diabetes 2011;60:A19.
110. Garber AJ, King AB, Del PS, et al Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial Lancet 2012;379:1498-507.
111. Meneghini L, Atkin S, Bain S, et al Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes [abstract] Diabetes 2011;60 (Suppl 1A):LB10-LB11.
112. Vaag A, Leiter LL, Franek E, et al Use of new basal insulin with a bolus boost (IDegAsp) in type 2 diabetes: comparison with biphasic insulin aspart 30 (BIAsp 20) [abstract] Am Diabetes Assoc 2012; Diabetes 2011;60 (Suppl 1A):1141-P.
113. Hirsch IB, Franek E, Courreges J-P, Mersebach H, Dykiel P, Bode BW Efficacy and safety of a new basal insulin with a bolus boost (IDegAsp) used once daily in combination with insulin aspart (IAsp) in people with type 1 diabetes [abstract] Diabetes 201 1;60:A292.
114. Heise T, Nosek L, Hovelmann U, Bottcher SG, Hastrup H, Haahr H Insulin degludec 200 U/ml is ultra-long-acting and has a flat and stable glucose-lowering effect Philadelphia, PA: American Diabetes Association; June 8-12, 2012.
115. Korsatko S, Deller S, Zahiragic S, et al Ultra-long-acting insulin degludec: bioequivalence and similar pharmacodynamics shown for two different formulations (100 U/ml and 200 U/ml) Lisbon, Portugal: European Association for the Study of Diabetes; September 12-16, 2011.
116. Bastyr EJ, Bergenstal RM, Rosenstock J, Prince MJ, Qu Y, Jacober SJ The novel long-acting insulin LY2605541 is superior to insulin glargine in lowering intra-day glucose variability and hypoglycemia event rate from continuous glucose monitoring (CGM) in patients with type 2 diabetes Philadelphia, PA: American Diabetes Association; June 8-12, 2012.
117. Bergenstal RM, Rosenstock J, Arakaki RF, et al Reduced nocturnal hypoglycemia and weight loss with novel long-acting basal insulin LY2605541 compared with insulin glargine in patients with type 2 diabetes Philadelphia, PA: American Diabetes Association; June 8-12, 2012.
118. Hollander PA, Blonde L, Rowe R, et al Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial Diabetes Care 2004;27:2356-62.
119. Quattrin T, Belanger A, Bohannon NJ, et al Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial Diabetes Care 2004;27:2622-7.
120. Mastrandrea LD Inhaled insulin: overview of a novel route of insulin administration Vasc Health Risk Manag 2010;6:47-58.
121. Moses RG, Bartley P, Lunt H, et al Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with type 1 diabetes: 1-year data from a randomized, parallel group trial Diabet Med 2009;26:260-7.
122. Rave K, Heise T, Pfutzner A, Boss AH Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes Diabetes Care 2007;30:2307-8.
123. Khedkar A, Iyer H, Anand A, et al A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects Diabetes Obes Metab 2010;12:659-64.
124. Kapitza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes Diabetes Care 2010;33:1288-90.
125. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults Am J Epidemiol 2004;159:1160-7.
126. Pollak M Targeting insulin and insulin-like growth factor signalling in oncology Curr Opin Pharmacol 2008;8:384-92.
127. Friberg E, Orsini N, Mantzoros CS, Wolk A Diabetes mellitus and risk of endometrial cancer: a meta-analysis Diabetologia 2007;50:1365-74.
128. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies Br J Cancer 2005;92:2076-83.
129. Larsson SC, Orsini N, Wolk A Diabetes mellitus and risk of colorectal cancer: a meta-analysis J Natl Cancer Inst 2005;97:1679-87.
130. Larsson SC, Orsini N, Brismar K, Wolk A Diabetes mellitus and risk of bladder cancer: a meta-analysis Diabetologia 2006;49:2819-23.
131. Larsson SC, Mantzoros CS, Wolk A Diabetes mellitus and risk of breast cancer: a meta-analysis Int J Cancer 2007;121:856-62.
132. Currie CJ, Poole CD, Gale EA The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 2009;52:1766-7.
133. Gunter MJ, Hoover DR, Yu H, et al Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women J Natl Cancer Inst 2009;101:48-60.
134. Redinger RN The pathophysiology of obesity and its clinical manifestations Gastroenterol Hepatol 2007;3:856-63.
135. Yang YX, Hennessy S, Lewis JD Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients Gastroenterology 2004;127:1044-50.
136. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM The type 1 insulin-like growth factor receptor pathway Clin Cancer Res 2008;14:6364-70.
137. Leitner JW, Kline T, Carel K, Goalstone M, Draznin B Hyperinsulinemia potentiates activation of p21Ras by growth factors Endocrinology 1997;138:2211-14.
138. Finlayson CA, Chappell J, Leitner JW, et al Enhanced insulin signaling via Shc in human breast cancer Metabolism 2003;52:1606-11.
139. Wang CC, Goalstone ML, Draznin B Molecular mechanisms of insulin resistance that impact cardiovascular biology Diabetes 2004;53:2735-40.
140. Zib I, Raskin P Novel insulin analogues and its mitogenic potential Diabetes Obes Metab 2006;8:611-20.
141. Zelobowska K, Gumprecht J, Grzeszczak W Mitogenic potency of insulin glargine Endokrynol Pol 2009;60:34-9.
142. Draznin B Mitogenic action of insulin: friend, foe or 'frenemy'? Diabetologia 2010;53:229-33.
143. Hemkens LG, Grouven U, Bender R, et al Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study Diabetologia 2009;52:1732-44.
144. Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK Insulin therapy and colorectal adenoma risk among patients with type 2 diabetes mellitus: a case-control study in Korea Dis Colon Rectum 2008;51:593-7.
145. Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB, Cryer B Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study Dig Dis Sci 2008;53:2486-94.
146. Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ Association of markers of insulin and glucose control with subsequent colorectal cancer risk Cancer Epidemiol Biomarkers Prev 2003;12:412-18.
147. Bonelli L, Aste H, Bovo P, et al Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy Pancreas 2003;27:143-9.
148. Komura T, Mizukoshi E, Kita Y, et al Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis Am J Gastroenterol 2007;102:1939-46.
149. Silverman DT, Schiffman M, Everhart J, et al Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer BrJ Cancer 1999;80:1830-7.
150. Pierce BL, Plymate S, Ostrander EA, Stanford JL Diabetes mellitus and prostate cancer risk Prostate 2008;68:1126-32.
151. Velicer CM, Dublin S, White E Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications Prostate Cancer Prostatic Dis 2007; 10:46-51.
152. Hansen BF, Glendorf T, Hegelund AC, et al Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10 PLoS One 2012;7:e34274.
153. U.S Food and Drug Administration Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention (draft) Rockville, MD: U.S Food and Drug Administration; February, 2008.